HLS Therapeutics Inc. (TSE:HLS - Free Report) - Equities researchers at Stifel Canada issued their Q1 2025 EPS estimates for HLS Therapeutics in a report released on Tuesday, March 25th. Stifel Canada analyst J. Keywood anticipates that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics' Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.43) EPS.
Separately, Stifel Nicolaus upped their price target on shares of HLS Therapeutics from C$3.50 to C$4.00 and gave the stock a "hold" rating in a research report on Wednesday, March 26th.
Read Our Latest Research Report on HLS
HLS Therapeutics Price Performance
HLS traded down C$0.03 during trading on Thursday, hitting C$4.63. The company's stock had a trading volume of 2,100 shares, compared to its average volume of 14,548. The firm's 50 day moving average price is C$4.19 and its two-hundred day moving average price is C$3.82. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. The stock has a market capitalization of C$103.01 million, a price-to-earnings ratio of -4.64 and a beta of 1.07. HLS Therapeutics has a 12 month low of C$3.00 and a 12 month high of C$5.48.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
Read More
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
